stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Operating cash flow
Insmed, Inc.'s operating cash flow for fiscal 2025 was −$935.0M, compared with −$683.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$595.6M. Over the past ten years it has ranged from −$935.0M (fiscal 2025) to −$100.7M (fiscal 2015) — the current reading is the lowest in ten years. Operating cash flow has fallen for 5 consecutive fiscal years. Insmed, Inc. ranks 599th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$935.0M | — |
| FY2024 | −$683.9M | — |
| FY2023 | −$536.2M | — |
| FY2022 | −$400.4M | — |
| FY2021 | −$363.3M | — |
| FY2020 | −$219.3M | — |
| FY2019 | −$250.6M | — |
| FY2018 | −$258.0M | — |
| FY2017 | −$159.6M | — |
| FY2016 | −$146.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$36.5M | — |
| Jun 2026 | −$88.8M | — |
| Mar 2026 | −$222.7M | — |
| Dec 2025 | −$247.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| EXEL Exelixis, Inc. compare | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $955.9M |
| GMAB Genmab A/S Sponsored ADR compare | $891.0M |
| INCY Incyte Corporation compare | $745.0M |
| ASND Ascendis Pharma A/S compare | $404.1M |
| BNTX BioNTech SE Sponsored ADR compare | −$277.2M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.0M |
| INSM Insmed, Inc. | −$595.6M |
| ROIV Roivant Sciences Ltd. compare | −$816.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement